Lung Cancer Considered podcast

ESMO 2026 Highlights – Part 1

0:00
1:26:37
Rewind 15 seconds
Fast Forward 15 seconds
In this episode of Lung Cancer Considered, Drs. Jacob Sands, Ferdinandos Skoulidis, and Jarushka Naidoo discuss key research highlights from ESMO 2026, including results from the DeLLphi-305 trial evaluating tarlatamab in extensive-stage small cell lung cancer and the KRAScendo-1 trial investigating divarasib in KRAS G12C-mutated NSCLC. The discussion also explores emerging immunotherapy strategies, including findings from the MOIO and OptiTROP-Lung06 studies, advances in predicting immune-related toxicities, and the potential implications of these developments for clinical practice. Jaruska Naidoo, MD Professor of Medical Oncology Royal College of Surgeons Consultant, Medical Oncologist at Beaumont Hospital X: @DrJNaidoo Instagram: jarushkanaidoo LinkedIn: https://www.linkedin.com/in/jarushka-naidoo-127a3b97/ Jacob Sands, MD Assistant Professor of Medicine, Harvard Medical School Associate Chief, Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute X: @sands_jacob Instagram: jacobsands LinkedIn: https://www.linkedin.com/in/jacobsands/ Ferdinandos Skoulidis, MD, PhD Professor, Department of Thoracic and Head and Neck Medical Oncology University of Texas MD Anderson Cancer Center

More episodes from "Lung Cancer Considered"